Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more
Market Cap & Net Worth: Ipsen SA (IPN)
Ipsen SA (PA:IPN) has a market capitalization of $13.34 Billion (€12.99 Billion) as of March 18, 2026. Listed on the PA stock exchange, this France-based company holds position #3250 globally and #12 in its home market, demonstrating a 2.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ipsen SA's stock price €157.70 by its total outstanding shares 82387028 (82.39 Million).
Ipsen SA Market Cap History: 2015 to 2026
Ipsen SA's market capitalization history from 2015 to 2026. Data shows growth from $4.68 Billion to $13.34 Billion (11.64% CAGR).
Index Memberships
Ipsen SA is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid 60
CACMD
|
$36.02 Billion | 11.23% | #2 of 55 |
|
CAC Mid & Small
CACMS
|
$48.16 Billion | 8.40% | #2 of 119 |
|
CAC All-Tradable
CACT
|
$487.04 Billion | 0.83% | #11 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$487.04 Billion | 0.83% | #11 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$487.04 Billion | 0.83% | #11 of 179 |
|
CAC Health Care
FRHC
|
$70.93 Billion | 5.70% | #2 of 36 |
|
EuroNext 100
N100
|
$415.48 Billion | 0.97% | #11 of 97 |
Weight: Ipsen SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ipsen SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ipsen SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.62x
Ipsen SA's market cap is 2.62 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
27.06x
Ipsen SA's market cap is 27.06 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.68 Billion | $1.52 Billion | $189.90 Million | 3.08x | 24.63x |
| 2016 | $5.35 Billion | $1.67 Billion | $225.90 Million | 3.20x | 23.68x |
| 2017 | $7.81 Billion | $2.01 Billion | $272.30 Million | 3.88x | 28.67x |
| 2018 | $8.91 Billion | $2.35 Billion | $389.50 Million | 3.80x | 22.88x |
| 2019 | $6.30 Billion | $2.69 Billion | -$54.90 Million | 2.34x | N/A |
| 2020 | $5.49 Billion | $2.69 Billion | $548.00 Million | 2.04x | 10.01x |
| 2021 | $6.58 Billion | $2.75 Billion | $646.60 Million | 2.39x | 10.18x |
| 2022 | $8.32 Billion | $3.16 Billion | $648.60 Million | 2.64x | 12.83x |
| 2023 | $9.03 Billion | $3.31 Billion | $644.40 Million | 2.73x | 14.02x |
| 2024 | $9.36 Billion | $3.57 Billion | $345.90 Million | 2.62x | 27.06x |
Competitor Companies of IPN by Market Capitalization
Companies near Ipsen SA in the global market cap rankings as of March 18, 2026.
Key companies related to Ipsen SA by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Ipsen SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Ipsen SA's market cap moved from $4.68 Billion to $ 13.34 Billion, with a yearly change of 11.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.34 Billion | +32.52% |
| 2025 | €10.06 Billion | +7.50% |
| 2024 | €9.36 Billion | +3.63% |
| 2023 | €9.03 Billion | +8.54% |
| 2022 | €8.32 Billion | +26.44% |
| 2021 | €6.58 Billion | +19.96% |
| 2020 | €5.49 Billion | -12.85% |
| 2019 | €6.30 Billion | -29.36% |
| 2018 | €8.91 Billion | +14.18% |
| 2017 | €7.81 Billion | +45.97% |
| 2016 | €5.35 Billion | +14.33% |
| 2015 | €4.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ipsen SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.34 Billion USD |
| MoneyControl | $13.34 Billion USD |
| MarketWatch | $13.34 Billion USD |
| marketcap.company | $13.34 Billion USD |
| Reuters | $13.34 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.